- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 27.03. | Scandion Oncology A/S: Scandion Oncology Announces Results of Annual General Meeting | 125 | GlobeNewswire (Europe) | The Annual General Meeting 2025 of Scandion Oncology A/S in liquidation (the "Company") was held on 27 March 2025 at 2:00 p.m.
All proposals were adopted in accordance with the notice.As such, the Company... ► Artikel lesen | |
| 13.03. | The observation status for Scandion Oncology A/S is updated | 173 | GlobeNewswire | On February 27, 2025, the shares and equity rights in Scandion Oncology A/S (the "Company") were given observation status with reference to information that the Company's board of directors would... ► Artikel lesen | |
| 13.01. | Scandion Oncology A/S: Scandion Oncology announces final data from the CORIST trial and is ready to move into a randomized phase II Proof of Concept trial in Colorectal Cancer | 136 | GlobeNewswire (Europe) | Scandion Oncology, an innovative drug efflux pump inhibition company using biomodulation capability to revert drug resistance, announces final data from CORIST trial part 1, 2 and 3. In this phase I/II... ► Artikel lesen | |
| 30.08.24 | Nasdaq Stockholm AB: Change of Certified Adviser for Scandion Oncology A/S | 470 | GlobeNewswire | As from September 1, 2024, Scandion Oncology A/S, will change Certified Adviser
to Vator Securities AB.
This information is distributed at the request of the Certified Adviser, Västra
Hamnen Corporate... ► Artikel lesen | |
| 18.07.24 | Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 3 | 252 | GlobeNewswire | At the request of Scandion Oncology, Scandion Oncology equity rights will be
traded on First North Growth Market as from July 19, 2024.
Security name: Scandion Oncology TO 3
--------------------------------------
Short... ► Artikel lesen | |
| SCANDION ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 18.07.24 | Nasdaq Stockholm AB: New equity right for trading, Scandion Oncology A/S TO 2 | 271 | GlobeNewswire | At the request of Scandion Oncology, Scandion Oncology equity rights will be
traded on First North Growth Market as from July 19, 2024.
Security name: Scandion Oncology TO 2
--------------------------------------
Short... ► Artikel lesen | |
| 11.07.24 | Nasdaq Stockholm AB: New last trading day for paid subscription units (BTU) of Scandion Oncology | 477 | GlobeNewswire | At the request of Scandion Oncology, the last trading day in Scandion
Oncology's paid subscription units will be changed from 2024-07-11 to
2024-07-15.
Instrument: Paid subscription units... ► Artikel lesen |
7 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PHATHOM PHARMACEUTICALS | 8,920 | +90,19 % | Phathom Pharmaceuticals Announces Positive FDA Decision to Recognize 10 Years of Regulatory Exclusivity for VOQUEZNA (vonoprazan) Tablets through May 3, 2032 | FLORHAM PARK, N.J., June 06, 2025 (GLOBE NEWSWIRE) -- Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT) today announced that the U.S. Food and Drug Administration (FDA) has approved Phathom's Citizen Petition... ► Artikel lesen | |
| AVIDITY BIOSCIENCES | 36,240 | +1,83 % | Avidity Biosciences, Inc.: Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN DIEGO, May 21, 2025 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics... ► Artikel lesen | |
| QIAGEN | 40,060 | -0,55 % | DEUTSCHE BANK RESEARCH stuft QIAGEN NV auf 'Buy' | FRANKFURT (dpa-AFX Analyser) - Deutsche Bank Research hat das Kursziel für Qiagen von 47 auf 50 US-Dollar angehoben und die Einstufung auf "Buy" belassen. Analyst Jan Koch zog in seinem am Dienstag... ► Artikel lesen | |
| ARCELLX | 68,10 | +2,81 % | Arcellx, Inc.: Arcellx Announces Its Participation at TD Cowen's 6th Annual Oncology Innovation Summit and Its Investor Event During EHA2025 | Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announced... ► Artikel lesen | |
| ARCUTIS BIOTHERAPEUTICS | 14,370 | +6,37 % | Arcutis Biotherapeutics, Inc.: Arcutis Biotherapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | WESTLAKE VILLAGE, Calif., June 06, 2025 (GLOBE NEWSWIRE) -- Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 5,485 | +20,02 % | Recursion Pharmaceuticals shares surge on AI model release | ||
| TARSUS PHARMACEUTICALS | 43,920 | -0,39 % | Oppenheimer assumes Tarsus stock at outperform on strong sales | ||
| BIONTECH | 95,35 | +0,05 % | Allianz gegen Krebs: BioNTech sichert sich Milliarden-Deal mit Bristol Myers: Aktie explodiert! | © Foto: picture alliance / Laci Perenyi | Laci PerenyiBioNTech erhält 1,5 Milliarden US-Dollar Vorschuss von Bristol Myers - für die gemeinsame Entwicklung eines vielversprechenden Krebswirkstoffs.... ► Artikel lesen | |
| VERA THERAPEUTICS | 22,760 | -25,69 % | Vera Therapeutics Announces Atacicept Achieved 46% Proteinuria Reduction in ORIGIN Phase 3 Trial in Adults with IgA Nephropathy | Atacicept ORIGIN Phase 3 trial met the primary endpoint of reduction in proteinuria (UPCR) at week 36; participants receiving atacicept achieved a 46% reduction from baseline and 42% reduction compared... ► Artikel lesen | |
| MOONLAKE IMMUNOTHERAPEUTICS | 46,880 | -3,99 % | ROUNDUP/Aktien New York: Knappes Plus - Gelassenheit trotz Zoll-Unruhen | NEW YORK (dpa-AFX) - Die US-Börsen haben am Dienstag knappe Kursgewinne erzielt. Die jüngst wieder aufflackernden, internationalen Handelsstreitigkeiten wegen der amerikanischen Zollpolitik scheinen... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 15,240 | +2,83 % | RBC Capital behält Outperform-Rating für Edgewise Therapeutics-Aktie bei | ||
| JANUX THERAPEUTICS | 26,210 | +5,86 % | Leerink cuts Janux Therapeutics price target to $89, keeps Outperform | ||
| EVOTEC | 7,060 | +0,94 % | Evotec Aktie: Ohne Übernahme sieht es schlecht aus! Auf diese Kursmarke kommt es an! | © Foto: Finanznachrichten (Symbolbild)Zwischen Kursrakete mit Übernahmefantasie und Korrekturmodus Richtung Süden. Der Biotech-Titel aus Hamburg liefert seit Wochen ein Wechselbad der Gefühle. Kann... ► Artikel lesen | |
| 89BIO | 10,250 | +3,12 % | 89bio, Inc.: 89bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SAN FRANCISCO, June 06, 2025 (GLOBE NEWSWIRE) -- 89bio, Inc. (the "Company" or "89bio") (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization... ► Artikel lesen | |
| TREVI THERAPEUTICS | 7,060 | +4,75 % | Trevi Therapeutics, Inc.: Trevi Therapeutics Announces Positive Topline Results from the Phase 2b CORAL Trial of Haduvio in Patients with Idiopathic Pulmonary Fibrosis Chronic Cough | Haduvio met the primary endpoint with statistically-significant reductions in 24-hour cough frequency across all dose groups (108 and 54 mg BID p
Patients saw a... ► Artikel lesen |
Das Unternehmen SCANDION ONCOLOGY A/S kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 0,002 Euro und damit +14,29 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu SCANDION ONCOLOGY A/S finden Sie auf Wallstreet Online.